Evolus, Inc. (EOLS) fair value analysis
Nasdaq · Updated 2026-09-07
Evolus, Inc. is a medical aesthetics company that develops and commercializes injectable aesthetic products for physicians and patients. The company operates primarily in the United States and also maintains a presence in select international markets.
Valuation status
Awaiting full valuationEOLS does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $6.05
- Sector
- Healthcare
- 12-month range
- $4.29–$6.82
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Overbought
- 50/200-day trend
- Mixed
- 52-week position
- The upper-middle quarter of its range
What our data shows for EOLS
- Shares are trading in the upper third of their 12-month price range of $4.29–$6.82.
- The 14-day relative strength index sits at an overbought 79.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for EOLS
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent EOLS news
TickrTrends' derived news-sentiment signal for EOLS is currently mixed, computed from recent coverage.
- Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future (insidermonkey.com, 2026-09-09)
TickrTrends take: Evolus achieving profitability represents a fundamental shift in the company's financial trajectory that typically warrants reassessment of valuation multiples in the healthcare sector. With TickrTrends currently awaiting full valuation data on EOLS, investors focused on valuation metrics should monitor whether this profit milestone translates into sustained earnings growth and operating margins that would support a normalized valuation framework. The company's concurrent investment in future growth initiatives will be a key variable in determining whether current or forward-looking valuation comparisons to healthcare peers are justified.
What people are saying
Follow the EOLS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is EOLS stock undervalued?
EOLS does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is EOLS's TickrTrends verdict?
EOLS is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is EOLS overbought or oversold?
EOLS's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.